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Can TRUS estimation of the Prostate volume predict the 
outcome of TURP in Chronic Urinary Retention? 
Abstract- 
Aim- To study whether prostate size influences the outcome of TURP in patients with  chronic 
retention. 
Methodology- This was a prospective study conducted in the department of urology CMC 
vellore , from 1st August 2011 to 31st January 2014. All patients with chronic retention 
presenting to the department and planned for TURP were enrolled. Patients were evaluated by 
IPSS scoring, digital rectal examination, TRUS estimation of prostate volume and intravesical 
prostate protrusion(IPP), BMI, creatinine and urine culture . Uroflometry and post void residue 
(PVR) was measured for those not on catheter. The resected specimen was measured in a 
weighing scale and post operative PVR was measured for all patients. Patients with urethral 
stricture, carcinoma prostate, proven neurogenic bladder, voiding dysfunction and vesical 
calculus were excluded.  
The primary end point was successful voiding (catheter free) with PVR of less than 150ml after 
the operation. 
 Results- We enrolled 139 patients with chronic retention in this study, 118 patients were 
evaluated. The mean age was 65 [65.54±8.735 (43-86)], and prostate volume was 47.23±26.75 
(8.71 to 172). Patients with large prostate volume (>40ml) had higher of successful outcome 
following TURP (p- 0.014). There was no significant correlation of the prostate size with age 
(Pearson correlation coefficient 0.142), BMI (Pearson correlation coefficient -0.026) and IPSS. 
Patients who present with acute on chronic retention had a significantly larger prostate (51.4 Vs 
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34.6ml, p=0.008) and greater intravesical protrusion (7.8 Vs 6mm). Digital rectal examination 
correlated well with TRUS volume (Pearson correlation 0.489). Intravesical prostate more than 
10mm seem to have a better outcome but it was not statistically significant (p- 0.370).   Ninety –
four percent had successful outcome after TURP (catheter-free), 8 patients required either CISC 
or indwelling catheter. 
Conclusion- Majority (94%) of the patients with chronic urinary retention had successful 
outcome after TURP. Patients with larger prostate are more likely to be catheter-free following 
TURP. However, in our study we could not establish correlation between IPP and outcome 
following TURP.  
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1. Introduction  
Urinary retention is a one of the most common and distressing emergency in urology. 
Though acute retention is more dramatic in presentation and more common, chronic retention is 
more obscure and may present to the outpatient clinic rather than as emergency (1). The 
incomplete emptying of the bladder and retention of large urine residue without the patient 
realizing it over a long period carries a guarded prognosis after surgery.  
Urinary retention is described as the inability to empty the bladder completely or not at 
all. It may be classify as acute or chronic. Acute retention is a sudden painful retention which 
drains less than 1000ml on catheterization. The International Continence Society(ICS) defines 
Chronic retention of urine (CUR)  as a non-painful bladder that remains palpable or percussible 
after the patient has passed urine(2). Such patients may be incontinent.  Chronic urinary retention 
is defined as post void residue of more than 300ml or painless palpable bladder after voiding or 
more than 1000ml drained after catheterization(3). Benign prostatic hypertrophy is the most 
common etiology in men. 
 Urinary retention is a common entity in elderly men in their 70s are five times more risk 
of AUR than men in their 40s and the most common etiology is benign prostatic 
enlargement.(4,5) Acute and chronic retention are common urological emergency, but the 
epidemiology data available in literature is mostly for acute retention with studies performed on 
the various parameters influencing the outcome in terms of successful trial void without catheter 
(TWOC) and after transurethral resection of prostate (6). Most of the trials involving benign 
prostatic hyperplasia treatments (either medical or surgical) tend to exclude chronic retention 
patients (7,8). The exact incidence and prevalence of CUR is unknown. Since it maybe 
asymptomatic studies of population associated with CUR fails to determine the overall burden of 
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CUR.  Epidemiology data in chronic urinary retention, especially in our country, are sparse and 
requires further studies.   
CUR generally develops gradually over the period of months to years and it is often 
asymptomatic. Patients with CUR may present with lower urinary tract symptoms such as 
frequency, urgency, overflow incontinence or urinary tract infection or acute on chronic 
retention. Though there are various causes of CUR in men like urethral stricture, prostate cancer, 
cerebrovascular accidents, multiple sclerosis, Guillain – Barre syndrome, psychogenic condition 
etc. benign prostatic hypertrophy is the most common etiology.  
Abram et al (1978) found that CUR patients with high voiding pressure had a better 
outcome following resection (3) but urodynamic parameters are less specific and sensitive in 
CUR. Besides patients with low pressure on urodynamic subsequently recover once the 
obstruction is relieved.  
Prostate volume and intravesical prostatic protrusion (IPP) has been found to have a 
positive correlation with severity of LUTS, acute retention (9). IPP is useful predictor of 
successful TWOC (10) and medical treatment, IPP more than 10mm do not respond well to 
tamsulosin (11).  In chronic retention however data is lacking as to whether prostate volume or 
intravesical prostate protrusion is associated or predict the outcome following TURP. The 
objective of this study is to find the correlation between prostate size and men with chronic 
retention.  
Prostate volume by digital rectal examination is unreliable and observer dependent, the 
accepted imaging modality is MRI and trans-rectal ultrasound (TRUS) though MRI tends to 
measure approximately 10% larger than the latter. TRUS is cheaper, easily available and easy to 
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learn. Prostate volume is calculated using the prolate ellipsoid volume formula (single 
observer/investigator).  
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2. Aim  
The aim of this study is to determine whether the prostate size influences the outcome of surgery 
in chronic retention patients. 
 
Primary objective- 
To find the correlation between TRUS estimated prostate volume and outcome after TURP. 
Secondary objective- 
To find the correlation between – 
1. IPP and outcome after TURP 
2. DRE and TRUS estimation of the prostate 
3. Prostate volume and Age, BMI, IPSS and gland resected. 
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3. Review of literature 
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3.1 Definition –  
 Patients with chronic urinary retention (CUR) presents with long standing large residue 
urine. Urologist commonly classify CUR as one of the following – 
 Chronic (silent) or acute on chronic retention (Painful/discomfort) 
High pressure or low pressure 
Obstructive or non-obstructive 
 There is no standard numerical value for defining chronic retention. Infact the ICS has 
not incorporated the residual urine volume in its definition (2). However, we find numerous 
values used to define CUR in literature. A patient is said to have CUR if  PVR > 250ml(12), 
300ml(3,5,7,13–15), and acute on chronic retention if the urine drained after catheterization is 
more than 1000ml (16).. 
 
3.2 Etiopathogenesis of CUR  
 3.2.1 Changes in the bladder in chronic obstruction- 
 CUR has a complex etiopathogenesis, obstruction causing detrusor hypertrophy, 
overactive bladder and subsequently grossly distended bladder with poor detrusor contraction 
(17). Long standing obstruction causes detrusor weakness and increased distension and even 
when the obstruction is relieved they may not void completely.  Urinary obstruction causes 
detrusor myohypertrophy with or without superimposed degeneration and subsequent excessive 
Extra Cellular Matrix (ECM) and elastic fibre deposits (hyperelastosis) between the widely 
separated muscle fibres which was postulated as the structural basis of chronic retention and 
increased bladder distensibility (18,19). Detrusor remodeling is due to degenerative and atrophic 
changes and elimination of smooth muscle, decrease in suburothelial myofibroblasts (20) and 
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compensatory hypertrophy of the remaining smooth muscle fibre, this can be diffuse or focal 
diffuse replacement fibrosis. This is seen in electron microscopic studies which show stereotyped 
patterns of the intracellular reorganization of smooth muscle cells in the detrusor of hyperactive 
bladder and in the prostate with benign prostatic hyperplasia, which represent both the 
compensatory and adaptive reactions (hypertrophied cells with minor ultrastructural changes) 
and the types of smooth muscle cell injury ("dark" electron-dense cells and "light" cells with 
pronounced lysis of myofilaments and discomplexation of organelles) (21).  Bladder 
trabeculation is due to an increase in detrusor collagen.    
3.2.2 Urodynamic findings-  
 Urodynamic studies classify CUR into high and low detrusor pressure retention. 
Those with high end pressure CUR have a better outcome and those with low pressure tend to 
fail after the obstruction is relieved (3,22). Besides being invasive, urodynamic is less specific 
and sensitive in identifying CUR. However there are reports of detrusor recovery and successful 
voiding following prostatectomy (23). Therefore even though it is not mandatory to do 
urodynamic in all patients with chronic retention(7) before operation those who fail to void 
completely after surgery will need urodynamic evaluation before the second operation to avoid 
incontinence (3). 
 
3.2.3 Neurosensory pathway –  
 Parys et al (1988) did a study on the integrity of the nerve supply of the lower 
urinary tract in a series of 22 patients with CUR due BPH. He found that 73% of the patients 
demonstrated a sensory suprasacral abnormality with intact spinal reflex arcs suggesting that 
though the sacral reflex pathways are intact there is a sensory / proprioceptive abnormality in the 
19 | P a g e  
 
higher centre which may be an adaptive mechanism to the presence of bladder outflow 
obstruction. (24) 
Treating this group of patients is non straight forward and outcome is not predictable due 
to which most clinical trials in urinary retention exclude these patients.(7) 
3.2.4 Pathophysiology of enlargement of the median lobe of the prostate   
BPH is a hyperplasia, that is, increase number of cells and not the size (hypertrophy) and 
this is confirmed by histological and pathological studies. The prostate volume does not correlate 
with the degree of obstruction or LUTS severity thus other factors play a role in causing 
obstruction- the dynamic sphincter and urethral resistance, prostatic capsule and the growth of 
the periurethral gland in the bladder neck that give rise to the “middle lobe”. 
Benign prostatic hyperplasia starts in the periurethral transition zone of the prostate which is near 
the bladder neck (25). The transition zone consists of periurethral glands just distal to the internal 
or preprostatic sphincter (26). At the base of the bladder, the internal longitudinal layer of 
bladder muscle converges and merges with the inner longitudinal muscle of the preprostatic 
sphincter; these are smooth muscles that play a key role in maintaining urinary continence and 
prevention of retrograde ejaculation.  
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Figure-1: Transition Zone of the prostate almost encircling the bladder neck. 
The bladder, bladder neck and the preprostatic sphincter are almost continuous and no clear 
demarcation either on MRI or TRUS especially when there is transitional zone hypertrophy. This 
hypertrophy can cause dynamic obliteration of the bladder neck presented in MRI protruding 
into the bladder producing a “ball-valve” mechanism of obstruction as in the figure (27,28). 
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Figure-2: Change in bladder neck anatomy with median lobe enlargement. (a) A distinct bladder 
neck is apparent but with progressive median lobe enlargement, the bladder neck is effaced (b, 
c) till it protrudes into the bladder (d) and is associated with ball valve obstruction. 
3.3 Measuring prostate volume:  
 Trans-rectal ultrasound (TRUS) is more reliable than clinical assessment. It gives better 
resolution images of the prostate and accurate measurement of prostate size(29,30). It is cheaper, 
safe, less invasive and readily available to urologist. TRUS and MRI gives similar prostate 
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volume though MRI is more accurate and MRI measures 10% larger than TRUS (17,31). TRUS 
tend to underestimate the actual surgical specimen by 10% in benign prostatic hyperplasia (32). 
The other parameter that can also be assessed more accurately  by TRUS than transabdominal 
ultrasound is the intravesical protrusion of the (33). In acute retention patients with large 
(>10mm) intravesical protrusion, medical management and trial without catheter is likely to fail 
and is a useful predictor for treatment (11). In CUR the role of intravesical protrusion of prostate 
is unknown. 
The use of TRUS was first reported in 1963 (34) but the development and clinical 
application was  described  by Watanabe  in 1974 (35).  They used 3.5 MHz transducers. 
Currently the state of the art TRUS are 5-8 MHz hand-held high-resolution, multi-axial planar 
probe with both transverse and sagittal imaging in real time with three-dimension reconstruction 
capabilities. 
Images of TRUS  
 
 
Figure-3: Transverse section of the prostate on the ultrasound and schematic diagram (17). 
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Diagnostic TRUS is an acceptable procedure and it can cause minor discomfort or not at 
all (36) [TRUS with prostate biopsy has more complication which will not be discussed here]. 
 
3.4 Intravesical prostate protrusion,  
 IPP can be measured by transabdominal suprapubic ultrasound  or  TRUS has a 
significant correlation with LUTS, acute retention and predictor of successful TWOC(37–39). 
Patients with more IPP were seem to be more obstructed regardless of the prostatic volume(33). 
IPP was graded into three grades-  
• Grade 1 (IPP1-5mm) 
• Grade 2 (IPP >5 up to 10mm) 
• Grade 3 (IPP >10mm) 
Grade 1 may benefit from TWOC while grade 3 would require definitive surgical 
procedure(39). Significant IPP is an independent factor predicting better post operative outcome 
in BPH in term of LUTS improvement (40).   
 
3.5 TRUS Vs Transabdominal-  
 Transabdominal ultrasound gives a reasonably accurate size of the prostate . Transrectal 
ultrasound is more accurate in predicting prostate volume than transabdominal ultrasound (41); 
TRUS also has an advantage of detecting abnormal inflammatory or malignant lesion. 
Transabdominal ultrasound tends to overestimate prostate volume in 50% of patients (42). But 
Huang et al found no statistical differences between TRUS and transabdominal ultrasound (43). 
Three dimension ultrasound has no advantage over TRUS (44). 
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3.6 Detrusor thickness or intravesical prostate protrusion? 
 Both detrusor thickness and IPP has been shown to be non-invasive indirect evidence of 
urinary  obstruction (33,38). But IPP seems to be a better tool in predicting bladder outflow 
obstruction in patients with BPE in terms of clinical and urodynamic variable with high 
specificity and positive predictive value (28)(2012). In patients with CUR the detrusor thickness 
is not a standardized variable due to gross distensibility of the bladder. 
 
3.7 Obesity and BPH-   
 Increased BMI, metabolic syndrome and sedentary life-style is associated with increased 
risk of benign prostatic hyperplasia and chance or undergoing prostatectomy (17,45). There are 
reports which state that the association of male LUTS, prostate volume and metabolic syndrome 
might be coincidental and related to old age (46). But even though obesity is associated with 
increased prostate volume across ethnic population but not worse lower urinary tract 
symptoms(47). A recent systematic review showed no differences were observed between 
subjects with or without Metabolic Syndrome for IPSS total or LUTS sub-domain scores. Meta-
regression analysis showed that differences in total prostate volume were significantly higher in 
older, obese patients and low serum HDL cholesterol concentrations (48). 
  
3.8 Management of CUR  
 Management is usually complex and urgent catheterization is not necessary because it is 
long standing and painless. Complication like renal failure, acute retention and urinary tract 
infections are uncommon in these group of patients but they requires judicious follow up as 
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outpatient, there are no predicting factors as to who required surgery (12). The need for 
catheterization is when there is upper tract dilatation and renal dysfunction (16) , when they 
present with acute on chronic retention, urinary tract infection or the presence of vesical calculi. 
Earlier urologist used to decompress the bladder gradually to avoid hematuria (1,49) but 
systematic analysis found hematuria and hypotension are usually mild and are of little clinical 
consequence. One must be cautious of post obstructive diuresis especially those with fluid 
overload state. Initial management must consist of judicous replacement of urine output and 
avoid fluid overload or dehydration and maintain electrolytes; most importantly elderly and 
moribund patient will need supportive care (50,51). 
 
3.8.1 Catheterization – CISC or Indwelling catheter? 
Ghalayini et al (2005) found that clean intermittent self catheterization (CISC)  did improve  the 
outcome after TURP by allowing the low pressure bladder to recover and the upper tract 
dilatation to settle. Those patients with high end-void and high end filling pressure had good 
outcome after the surgery. The common complication of CISC in this study was bleeding or 
infection or both. However this study did not include the prostate volume as a study parameter. 
CISC may be an option for patients with CUR who are unfit for anesthesia or for surgical 
procedures (13). 
 Indwelling catheter may be an option for men unfit for surgery and who cannot do CISC 
however, guidelines and studies on long term use are not there (52–54). Besides the discomfort 
and periurethral suppurative complication, chronic indwelling urethral catheter also become 
coated with bacterial biofilm and struvite crystals. Therefore suprapubic catheter should be 
considered even in men with CUR unfit for surgery or CISC (55). 
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 There are few reports of the use of prostatic stent in men with CUR but the outcome is 
unknown (56,57). 
 
3.8.2 Surgical intervention -  
Transurethral resection of prostate remain the treatment of choice for CUR due to BPE for those 
fit for operation, patients primed with preop CISC may be valuable (13,16). TURP is more 
effective than Laser ablation in CUR in term of symptom score, maximum urinary flow and 
failure (CLasP study 2000) (15) with 91% success in resection vs 63% for those with laser 
therapy. However with the advances in laser technology Holmium Laer Enuclation of Prostate ( 
HoLEP) and Photoselective Vaporization of the Prostate are also effective procedures in 
improving parameters in men with CUR; Jaeger et al (2014) found HoLEP had 99% catheter-free 
or successful outcome (14). Both the above studies did not have urodynamic evaluation before 
the operation. Schelin et al (2001) and Aagaard et al (2013) reported Transurethral microwave 
thermo therapy as a treatment option for CUR patients unfit for surgery with 77% catheter free 
and improvement in quality of life (58,59). 
 
3.8.3 Medical intervention- 
 There are almost no literature for medical therapy for chronic retention in men due to 
BPE. 
 3.8.4 Neuromodulation –  
 Sacral neuromodulation is a treatment option for non obstructive chronic urinary 
retention with sensory impairment. Studies done on women with refractory retention and men 
with unexplained non obstructive CUR showed promising results but the data are small for 
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significant conclusion (60,61). There are no studies on neuromodulation on CUR who fail to 
void after TURP. 
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PART - II 
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PART - II 
Aim and objective 
The aim of this study is to determine whether the prostate size influences the outcome of surgery 
in chronic retention patients. 
 
Primary objective - 
To find the correlation between TRUS estimated prostate volume and outcome after TURP. 
Secondary objective - 
To find the correlation between – 
1. IPP and outcome after TURP 
2. DRE and TRUS estimation of the prostate 
3. Prostate volume and Age, BMI, IPSS and gland resected. 
 
Methodology: 
In this study we prospectively studied men with chronic urinary retention due to benign 
prostatic hyperplasia presenting to our institution from 1st August 2011 till 30th January 2014.  
Definition- Using the ICS definition, CUR included those patients whose bladder is 
palpable or percussable even after voiding (2), or PVR of ≥300ml or ≥ 1000ml when in acute on 
chronic presentation (3) 
Inclusion criteria- All CUR patients undergoing TURP in our institution. 
Exclusion criteria- We excluded patients with-  
• Urethral stricture,  
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• Carcinoma prostate,  
• Proven neurogenic bladder & voiding dysfunction  
• Vesical calculus. 
CUR patients not fit for surgery or those who opted for CISC or indwelling catheter were 
not included in the treatment outcome analysis.  
Patients were consented and evaluated by IPSS scoring, digital rectal examination, TRUS 
estimation of the prostate volume and intravesical protrusion, BMI, creatinine, uroflow-post void 
residue (PVR) for those not on catheter, urine cultures, gland resected during TURP and post op 
PVR was also recorded.  
TRUS was done on Flex Focus 400 ultrasound machine (BK Medicals®, Denmark) using 
an 8808e Prostate Biplane transducer (BK Medicals®, Denmark) ultrasound probe with a 5 - 10 
MHz frequency range and 3 – 60 mm focal range. This probe gives simultaneous sagittal and 
transverse real-time images (62). It can also be use for side firing TRUS guided prostate biopsy. 
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Figure-4: Flex Focus 400 BK medical Ultrasound Machine and the transrectal probe 
 
Figure-5: Transrectal probe. 
The Institutional Review Board of the Christian Medical College approved the protocol 
(IRB- No.8253) and informed consent were obtained from all patients.  
Statistical analysis –  
 Descriptive statistics of the data collected were tabulated. Pearson correlation coefficient 
was used to describe the relation between different parameters. Data were analyzed using SPSS® 
16 (SPSS, Chicago). 
 
Sample size 
 A pilot study was done for 6 months and the actual sample size was calculated. Based on 
literature for acute retentions the prostate volume estimation from Djavan et al (23) (81 patients) 
and the pilot study we arrived at the following table- 
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Single mean – Estimating the population mean  
 Djavan et 
al*  
Djavan et 
al*  
Pilot study♠  Pilot 
study♠  
Pilot study♠  Pilot 
study♠  
Standard 
deviation  
17.2  17.2  31.2  31.2  31.2  31.2  
Absolute 
precision  
3  5  3  5  7  8  
Desired 
confidence 
level (%)  
95  95  95  95  95  95  
Required 
sample  
126  47  416  150  76  58  
*Bob Djavan et al Urodynamic Assessment Of Patients With Acute Urinary Retention Vol 158, 
1829-1833 J Urol 1997 (23) 
♠Pilot study   
 
 
 
 
The above was derived using the following formula- 
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n=(z2 1-α/2σ2)/d2 
 The sample size calculated was 150 with the absolute precision of 5.  
 The images were stored on the ultrasound machine and transferred to the CD and the 
Hard disk. The image prints were filed with consent forms.  
 
Measuring Prostate volume  
The prostate was measure using prostate formula - π/6 x Height (AP diameter) x Width 
(Transverse diameter) x Length (longitudinal diameter) (17). 
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Figure-6: Measuring prostate volume 
Measuring Intravesical prostate protrusion IPP– 
IPP was measured from the TRUS images in the Machine itself. A line across the bladder 
neck is drawn and IPP is measured as a line from the tip to the intravesical prostate dropped 
perpendicular to the line across the bladder neck (9).IPP was graded to three groups (39) –  
Grade 1 (IPP1-5mm),  
Grade 2 (IPP >5 up to 10mm) and  
Grade 3 (IPP >10mm). 
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Figure-7: Measuring intravesical protrusion of prostate ( Dist 3 is the IPP) 
 
Figure-8: Measuring intravesical protrusion by TRUS 
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Results 
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Results  
There were 910 patients who underwent TURP from 1st August 2011 to 31st January 2014. A 
total of 139 patients were identified as chronic urinary retention, enrolled for the study and 
planned for TURP. Of the 139, 21 patients were later excluded and only 118 patients were 
included for analysis (diagram)The median age was 65 [mean 65.33±8.7 (43-86)] with a median 
duration of symptoms of 12 months (range 1 month to 15 years). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Variable  Median  Mean ± standard deviation (range)  
Age  65  65.54±8.735 (43-86)  
BMI  22  22.139±3.9006 (14.1-38.4)  
IPSS  23.5  21.39±6.489 (3 to 34)  
PVR (ml)  441  433.96±132.6 (280-742)  
Duration of 
symptoms (months)  
12  21.89±24 (1 month to 15 years)  
DRE clinical (cc)  30.0  31.82±11.6 (15-90)  
TRUS prostate 
volume (ml)  
43.3  47.23±26.75 (8.71 to 172)  
IPP (mm)  5.9  7.5 ±6.5(0-20.6)  
Gland resected 
(grams)  
20.0  22.1±16.6 (0-104)  
Pre op creatinine 
(nadir) (mg%)  
1.38  1.5 ±0.7(0.6-5.7)  
PSA* (pg/ml)  7.7  14.5±26.5(0.43-143)  
*PSA is not done routinely in our institute but it was done for 28 patients for 
insurance purposes (all had BPH).  
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Twenty one patients excluded after consent- 3 patients had adenocarcinoma prostate, 2 
patients had transitional cell carcinoma bladder, 1 had TCC of the bladder requiring radical 
cystectomy, 3 patients had vesical calculus, 4 patients opted later for CISC and indwelling 
catheter and 6 had incomplete data or loss to follow up and one patient underwent open 
prostatectomy. 
 
 
Figure-9: Consort diagram 
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Prostate volume –  
Prostate volume Vs Age- The median size of the prostate is 43.3 ml [48.1±28.2 (8.71 to 
172)] Prostate volume showed a positive correlation with age (Pearson Correlation 0.142). 
 
Figure-10: Age and TRUS prostate volume in patients with chronic retention 
Prostate volume and DRE- 
 Digital rectal examination (DRE) had a significant correlation with TRUS prostate 
volume [Pearson Correlation 0.489]. 
 
Figur-11: Clinical digital rectal examination estimation of prostate size comparable to TRUS 
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Prostate volume and PSA  
 The larger the prostate volume, the higher is the PSA value [Pearson correlation 0.750]. 
All patients had benign prostatic hyperplasia on histopathology. 
 
Figure-12: Prostate volume and PSA  
Prostate volume and glands resected. 
 The weight of the TURP chips were correlating with the volume of the prostate [Pearson 
Correlation 0.807] 
 
Figure-13: Prostate volume and glands resected by TURP 
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Prostate volume and lower urinary tract symptoms 
 There was no correlation between Prostate volume and severity of LUTS based on IPSS 
score. [Pearson correlation -0.221] 
 
Figure-14: Prostate volume and IPSS 
Prostate volume Vs BMI 
 Prostate volume did not correlate with BMI, [Pearson Correlation -0.026]. 
 
Figure-15: Pearson Correlation diagram of BMI and Prostate volume. 
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 All patients were admitted 2 to 3 days earlier and were given pre operative parenteral 
antibiotics for at least 48 hour before they underwent TURP (Most patients were on indwelling 
urethral catheters and catheter changed within one week prior to TURP). Catheter was removed 
2 to 5 days after the operation. 
 
Prostate volume and outcome – 
 Patients with larger prostate (>40 ml) had better outcome (98% were catheter-free). 
Those with PV <20ml and those between 20 and 40ml had 82% successful outcome each. 
TRUS volume in 
ml (n) 
Outcome successful 
Catheter-free 
Outcome failure CISC or 
indwelling catheter 
P (Fisher’s 
exact test) 
<20 (13) 11 2(18%)  
0.014 20-40(37) 32 5 (13.5%) 
>40 (68) 68 0 
 
Intravesical prostatic protrusion (IPP)- 
 Out of 118, IPP was available for 110 patients. Patients with grade III IPP had 98% 
catheter-free (successful) outcome, grade II had 100% success and grade I 88%; those with 
larger IPP has a good chance of success after TURP in CUR. There is a positive correlation 
between IPP and prostate volume [Pearson correlation 0.54] 
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Figure-16: Correlation between IPP and prostate volume  
 Correlations Summary  
  Pros vol(cc) IPP IPSS Qmax Gland resected 
Pros vol(cc) Pearson Correlation 1 .540** -.221 .047 .807** 
Sig. (2-tailed) 
PVALUE 
 .000 .232 .828 .000 
N 118 107 31 24 113 
IPP Pearson Correlation .540** 1 -.004 .324 .590** 
Sig. (2-tailed) .000  .984 .131 .000 
N 107 107 31 23 103 
IPSS Pearson Correlation -.221 -.004 1 -.047 -.111 
Sig. (2-tailed) .232 .984  .920 .559 
N 31 31 31 7 30 
Qmax Pearson Correlation .047 .324 -.047 1 .098 
Sig. (2-tailed) .828 .131 .920  .663 
N 24 23 7 24 22 
Gland resected Pearson Correlation .807** .590** -.111 .098 1 
Sig. (2-tailed) .000 .000 .559 .663  
N 113 103 30 22 113 
**. Correlation is significant at the 0.01 level (2-tailed).    
 
 
44 | P a g e  
 
Comparing the outcome of TURP based on IPP value 
 Though there seem to be a positive correlation of IPP and the outcome of TURP but it 
was not statistically significant [p = 0.370]. 
 
 
 
 
 
 
 
 
 
Based on the presentation we CUR  divided into two groups 
 Majority of the patients were on catheter for acute on chronic or renal dysfunction. We 
divided the patients in two group-  
 Group A – Chronic retention not on catheter (PVR ≥ 300ml) 
 Group B – Acute on chronic retention (PVR ≥ 1000ml) 
IPP(mm) Outcome successful 
(Catheter-free) 
Outcome failure 
(CISC or  
indwelling catheter) 
P (Fisher’s Exact test ) 
<5 (46)  41  5 (12%)   
0.370 >5 – 10 (24)  23 1 (4%)  
>10 (37)  36 1 (2.7%)  
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Comparing the profile of the two groups (the mean of each group was calculated and test for 
difference analysis) 
 Group A (20) 
Without catheter 
Group B (98) 
Catheterized 
P 
Sig (2-tailed) 
Age  65.45 65.56 0.959 
Duration of symptoms 
(Months) 
21.94 21.88 0.872 
IPSS  25 20.69 0.178 
Prostate volume (cc) 14.39 27.89 0.013 
Intravesical prostatic 
protrusion (IPP) 
5.36 6.32 0.103 
BMI 23.56 21.8 0.074 
Nadir creatinine pre 
operatively 
1.15 1.599 0.190 
Glands resected  16 22.9 0.144 
Post op PVR (ml) 143.10 107.49 0.821 
Failure to void  1 (5%) 7 (7%) 0.551 
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 The age and IPSS in both patient group were similar. Patients in acute on chronic 
retention group, requiring catheterization, had higher prostate volume, IPP and volume of gland 
resected statistic significance was seen onlywith prostate volume. 
 There was no morbidity or mortality of the study patients, 90% of patients in this study 
had urine culture positive but none had septicemia. 
None required blood transfusion.  
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Discussion 
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Discussion: 
Chronic retention is an under diagnosed condition in benign prostatic hyperplasia as it is 
asymptomatic most of the time. It is not well define and there are no standard guidelines for the 
management of this condition. It is common in elderly men over the age of 50, who presents with 
lower urinary tract symptoms- frequency, urgency or urgency incontinence mainly due to 
overflow incontinence. When evaluated, they have large residue or mild lower abdominal 
discomfort with disproportionately large, palpable bladder. There are several factors associated 
with LUTS and the progression to acute retention and a positive correlation with age, prostate 
volume and IPP has already been established (9,38). However, because the outcome of treatment 
in CUR is unpredictable clinical trials in BPH tends to exclude these patients (7). To our 
knowledge this is a first prospective study on prostate volume and IPP in chronic urinary 
retention 
There are only a few case control and randomized control trials on CUR though they 
dealt with varied etiologies of CUR, BPH was the most common. Van Vuuren et al (2011) 
reported in the retrospective study that patients of BPH with CUR were at least five year old than 
those with AUR but both had large prostate (>50cc) (63). Though our study did not include acute 
retention we found that prostate volume in CUR is also large 47.23±26.75cc. In fact majority of 
our patients with large prostate had a successful outcome after TURP. 
 Mariappan et al found a positive correlation of 0.59 between IPP and Prostate 
volume in acute retention, Lim et al  and Franco et al also found a positive correlation of 0.61 
and 0.45, respectively (33,38,64) in BPH. Olmsted county study found a strong correlation 
between IPP and prostate volume in a community based sample (9). Our study also found a 
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positive correlation of 0.54 even for patients with chronic retention. Like in acute retention and 
BPH (10), IPP seem to be a predictor for successful outcome following TURP even in CUR, 
though not statistically significant.  
 As expected  the PSA value increases with the increase in prostate volume, as  shown in 
the Olmsted study (65).   
An audit by Emberton et al found that CUR comprises up to a 25% of men undergoing 
TURP in the UK (66). There were 910 TURP’s being done during the time period of the study in 
our institution and CUR patients were 139 (15%). Though only 118 were analyzed 111 patients 
were catheter- free after TURP. The overall success or TURP is 91% in the CLasP study (15) 
and our study showed 94% were catheter free after TURP.  Health related quality of life (HRQL) 
and voiding  improved after a successful TURP therefore, CUR patients should be offered TURP 
(7,13).  
There are studies based on urodynamic parameters where high end filling pressure is a 
good indicator of a successful outcome (3,13) but subsequent studies showed that even low end 
filling pressure patients do recovered after the obstruction is relieved (23).  Men over 80 years 
old, even with unfavorable urodynamic parameter do recover subsequently (23) and they too 
have better HRQL following a successful resection (67). Therefore Urodynamic study is not 
mandatory before TURP in CUR (7). 
 There were very few patients in this study who did not require pre operative 
catheterization and had a good outcome after the surgery suggesting that not all patients with 
CUR and normal renal function require catheterization or CISC. But if surgery is delayed for any 
reason CISC is a useful option ensuring bladder recovery before the surgery (13).   
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  This study even though prospective has several drawbacks of a single operator. Acute 
retentions were not studied for comparison. Detrusor thickness and pressure flow were not done. 
The quality of life is an important aspect which needs assessment especially in our country 
where men want to avoid catheter at all cost. 
The definition, diagnosis and management of chronic urinary retention in men with BPH 
still need to be standardized and guidelines need to be established in management.  We hope this 
study will contribute to the understanding of chronic urinary retention in men with BPH. 
Considering the low incidence of CUR a multicenter study will yield a better result.  
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Conclusion 
Majority (94%) of the patients with chronic urinary retention had successful outcome after 
TURP. Patients with larger prostate are more likely to be catheter-free following TURP. 
However, in our study we could not establish correlation between IPP and outcome following 
TURP.  
Chronic retention patients with large prostate, longer intravesical protrusion are risk factors for 
acute on chronic retention but do not alter the outcome after surgery. Prostate volume does not 
increase significantly with age and BMI even in patient with CUR. 
Digital rectal examination correlates with TRUS prostate volume estimation. 
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Annexure:  
Consent form:  
Informed consent for patients with chronic retention 
undergoing TRUS for prostate volume estimation. 
Introduction- 
We are conducting a research to study if the findings in an ultrasound scan for patients with 
problem similar to yours will help predicting the successful voiding. In order to do that, we need to do an 
additional ultrasound scan and the scanner device is introduced about an inch through the anus, to study 
the prostate gland. This procedure is not regularly done for patients undergoing TURP. 
 
Risk  
 There will be no major risk or treatment complication after TRUS volume measurement. There 
may be minimal discomfort introducing the probe but this type of scanning is frequently done in the clinic 
and most patients do not have any discomfort. 
 
Compensation 
 You will not be entitled to any compensation for participating in the study and you will not be 
charged for performing this procedure. In the rare event of finding any changes in the scan that may need 
change in your treatment plan, the findings will be utilized for your treatment. 
 
Confidentiality- 
Your name will be kept secret and will not be used during assessment of results and data analysis 
and results.  
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Your participation is voluntary and if there is discomfort during the procedure and does not want 
to participate in the study you are free to discontinue. The treatment will continue as planned by your 
doctor. 
 
Data to be collected 
The standard investigations before TURP reports will be collected along with the TRUS volume 
will be serum creatinine, blood group, urine culture, biopsy report, blood pressure, body mass index and 
operation records.  
 
Follow up 
No additional follow up is required apart from the routine  follow up that is advised after this operation. 
First follow up- After the operation before you go home (If you stay far from Vellore) 
Second follow up- At 3 months 
You may receive a phone call from the doctor doing this study.  
Contact details of the investigating doctor- 
………………….. 
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Informed consent to participate in TRUS prostate volume estimation in chronic urinary 
retention. 
Study: Can TRUS estimation of the prostate volume predict the outcome of TURP in chronic 
Urinary Retention? 
Study number: 
Subject’s initial:_______ Subject’s name:________________________________ 
Date of birth/age:_______________ 
I. I agree to participate in the TRUS prostate volume study.  
II. I confirm that I have read the information sheet dated____________ and I have been 
explained in my language and I have consented for examination and allow the transrectal 
scan measurement of my prostate. 
III. I understand that my participation in the study is voluntary and I am free to withdraw at 
anytime, without affecting my treatment. 
IV. I understand that my identity will not be revealed to third party or published without my 
consent. 
V. I agree to allow using my data for analysis and scientific studies. 
 
Signature of the subject/study patient 
________________ 
Date  
Name 
Signature of the investigator 
Date  
Name 
 
Signature of the witness 
Date 
Name 
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Study Proforma 
Clinical Research Form 
TRUS prostate volume in acute and chronic retention undergoing TURP 
 
Name: _______________________________________  Age:_______ 
Hospital No: 
Address: 
 
Phone no: 
Mobile no (local): 
Mobile no (Home): 
Email: 
Weight (Kg)-   Height(cm)-    BMI- 
Pulse-  BP(mmHg)- 
Duration of symptoms(months)- 
 
IPSS 
Medications 
Alpha blockers- 
5α-reductase inhibitors- 
 
Date of retention-  Duration on catheter (months)- 
Volume of urine after catheter insertion________ 
 
Comorbidities- 
Diabetes Mellitus_____ (year of diagnosis_____) Hypertension_____(year of diagnosis____) 
___________ Others _____________(year of diagnosis)____________ 
 
Clinical examination 
Genitalia_____________ 
Hernia__________ 
DRE   Prostatic nodule  BCR________ 
TRUS Prostate dimension 
 
AP 
diameter(mm) 
Transverse 
diameter (mm) 
Longitudinal 
distance (mm) 
Prostate 
volume (cc)  
Intravesical 
prostate 
protrusion 
     
 
Intravesical prostate- 
Intravesical length(mm)______ 
 
Intravesical/length ratio______ 
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Pre op Uroflow if not catheterised  
 
Qmax(ml/s)-  Voided vol(ml)- PVR(ml)- 
 
 
Pre operative investigations- 
Urine culture- 
 Organism- 
    
    
    
    
    
    
    
    
 
Creatinine (mg/dl)-________ 
Blood group- ___________ 
 
Operative findings 
Which lobe enlarged? 
Volume resected (gm)- ___________ 
Volume of glycine used (litres)- _________ 
Volume of saline used (litres)- _________ 
Blood transfused 
Biopsy  
Complications- 
Post operative investigations 
urine culture  
Creatinine 
 
Follow up at one week 
Symptoms   IPSS 
Uroflow Qmax  Voided vol  PVR 
 
Follow up at three months 
Symptoms   IPSS 
Uroflow Qmax  Voided vol  PVR 
Contact details of the investigating doctor- 
…………………. 
 
Date of stu Name Hospital numbeAge Unit DM HTN other comoduration of  IPSS Alpha bloc  5α reducta date of cat Immediate  Date of Sx Qmax Voided Vol PVR TWOC height(cm)
08.10.12 Velu 257653F 65 No No 2 Jul-12 1000 11.10.12 400 Failed 1 167
15.09.11 Asoke Mukherjee 000741F 59 No 2011 12 25.7.11 1000 742 155
19.05.12 Krishna Pada Mondal 161779F 75 No No 12 NA NA Not catheteCUR 21.05.12 0.5 556 162
27.6.13 Bikash Kanti Saha 499746F 55 No Yes Nil 1 CUR 27.6.13 6.9 507 320 158
27.6.13 Vasu Deva Rao 489402F 50 No Yes CKD 8 Yes No 24.3.13 1000 26.6.13 165
19.08.12 Yogendra Prasad Sinha 255534F 47 No No Chew tobac 48 24.07.12 1000 20.08.12 >300 171
28.07.12 Ekambaram 227642F 86 No Yes 60 23.06.12 1000 26.07.12 failed 1 162
10.7.13 Harikrishnan M 546337C 70 Yes Yes  16 1.13 1000 11.7.13 once failed 165
23.6.13 Swapan Modak 499233F 53 No No 1 25 No No 14.6.13 1000 24.6.13 527 None 156
26.7.13 Devanandan Prasad Sah330256C 63 Uro1 No Yes asthma 60 24 Yes Yes Not catheteCUR 26.7.13 3.7 98 387 None 162
11.09.12 Sathya Prasad 242431F 56 no no 72 Yes Yes Not catheteCUR 13.09.12 5 150 634 168
02.12.12 Budu Ram Shaw 329091F 66 Yes Yes 2 30 Yes CUR 3.12.12 3.8 75 558 NA 170
13.09.11 Annamalai 033903B 79 Yes Yes 3 02.06.11 1000 03.09.11 158
23.06.13 Govindaraji  C 668279D 78 Uro1 No No Smoker 24 25 No No 7.4.13 1000 26.6.13 162
08.05.12 Kannu Samy K 144644F 65 No No 48 No No May-12 1000 Failed 2 161
31.07.11 Gilbert 144078(Old) 62 No No 10 days 18.07.11 1000 NA NA NA 1 165
17.01.12 Ram Sakal Ram 897109C 58 No Yes 12 1000 14 162
16.9.13 Dulal Chandra Sahu 645454F 67 Uro1 No No Smoker 24 23 No No 14.6.13 1000 17.9.13 None 161
10.7.13 Laxmi Prasad Ramtel 858472D 60 Yes Yes Nil 120 27 Yes No 9.4.13 1000 15.7.13 once failed 167
08.01.13 Sanatan Chakraborty 382121F 64 No No Nil CUR 14.1.13 7.7 125 318 165
30.05.12 Bijay Singh 191222F 64 Yes Yes CRF 12 11-Dec 1000 31.5.12 155
15.7.13 Gobinda Chandra Das 430618F 53 No No Nil 12 17 No No 16.3.13 1000 15.7.13 3.8 144 300 None 150
15.01.12 Joseph R. Raju 105739B 71 Yes Yes Smoker 30.12.11 1000 16.01.12 163
04.08.11 Jahar Das 932939D 54 Uro1 No 6 years COPD 6 1000 05.08.11 162
22.01.12 Paramasivam A C 791659D 62 No 2years IHD 24 No Not catheteCUR 30.01.12 4.3 141 300 NA 159
24.10.11 Meganathan K. 013081F 67 No No 48 29.08.11 1000 Not done 164
08.10.12 Prahlad Prasad 951269C 74 Uro1 No No Chew tobacco 29.09.12 1000 09.10.12 Not done 165
15.7.13 Munirathinam 476366F 63 No No Nil 1 14 No No 3.6.13 1000 15.7.13 165
03.10.12 Pratap Singh 274686F 65 Yes Yes Psychiatry 5 18.09.12 1000 04.10.12 164
22.01.12 Shafi Ahmed 084078F 75 No No 6 21 No No Not catheteCUR 23.1.12 0.5 90 300 158
05.09.11 Haripandurangan K 789823C 62 2year No 12 05.08.2011 1000 failed 1 168
17.09.12 Ramalingam K 254425F 83 Uro1 20.08.12 1200 17.09.12 155
05.06.12 Anandan S P 186450F 57 No No 22.04.12 1000 5.06.12 Not recordable >600 Failed 3 159
20.8.13 Syed Hazrat Basha 646772F 72 No No Nil 13 No No 16.8.13 1000 Not operated 171
23.6.13 Sunil Kumar Dutta 011239F 53 No Yes Nil 120 24 Yes No 30.4.13 1000 24.6.13 159
23.04.12 Suriyakanta Mondal 109727F 56 No No Smoker 60 28.12.11 1500 25.04.12 174
24.09.12 Ramjag Ram 294239F 67 Uro1 8 Yes Not catheteCUR 24.9.12 0.5 256 385 159
05.03.12 Kanai Giri 101023F 61 Uro1 No No Smoker 96 24.12.11 1000 7.03.12 168
26.03.12 Nageshwar Sharma 156682F 64 Uro1 No No  6 11-Mar 1000 27.03.12 155
29.5.13 Madan moham Das 432645F 63 yes no 24 25 No No Not catheteCUR 30.5.13 4.9 257 444 169
21.8.13 Balaraman A 629007F 65 No No Smoker 2 No No 12.7.13 1000 22.8.13 None 165
08.09.11 Bharat Kundu 995641D 70 No No 6.11 1000 08.09.11 156
03.10.12 Anil Swarnakar 284542F 68 No No 8 5 No 08.07.12 1000 04.10.12 165
27.8.13 Panchatcharam 288540old 60 No No 12 24 No No 6.7.13 1000 No 165
30.05.12 Sukumar Talukdar 188913F 62 2002 2002 Smoker 3 24 15.05.12 1000 165
10.7.13 Ameer Jan S. 605042F 60 No Yes 24 28 No No 21.5.13 1000 12.8.13 None 158
14.03.12 Ranga Reddy 120230B 71 Yes Yes IHD 24 24 Not catheteCUR 29.03.12 10.2 150 518 173
02.08.11 Mani C 976804A 54 No 2months 2 Not catheteCUR 3.8.11 5.9 131 380 155
21.08.11 Provat Dey 004664F 65 No No 24 No No 12.8.2011 1000 no 150
15.7.13 Chidambaram M G 613948F 66 Uro1 Yes Yes Nil 6 15 28.6.13 1300 16.7.13 None 170
03.09.12 Logu K S 471751B 68 Uro1 No No 12 12-Jun 1000 failed 1 165
01.08.12 Hari Pada Kayet 242678F 58 No No Jun-11 1000 01.08.12 6.9 205 494 164
7.8.13 Meshak D 229521F 78 No No 1 24 No No 1.12.12 1000 12.8.13 None 160
21.08.11 Sukhalal Saha 996911D 79 No Yes IHD 36 12 12 CUR CUR 22.08.11 7.5 152 300 160
21.8.13 Ram Gati Singh 416655F 73 No Yes CUR 22.8.13 9.3 315 280 167
15.05.12 Naresh Prasad 146266F 63 Yes No GUTB 4 25 NA NA Not catheteCUR 17.05.12 9.9 145 300 165
6.8.13 Ramdeni Saw 636399F 80 No Yes CVA 1 23 No No 12.7.13 2000 12.8.13 None 158
25.09.12 Sharalamsekh 294398F 59 No No Smoker 4 Sep-12 1500 05.11.12 162
19.08.11 Dhamodiran 987675D 62 No 1 year 4 4 4 CUR CUR 19.08.11 NA 300 162
26.09.12 Mani Sundharam 289097F 58 Uro1 No Yes 24 Yes Yes 17.08.12 1200 28.09.12 failed 3 170
16.8.13 Baneshwar Barai 622855F 67 No Yes 28 No No 2.7.13 1000 16.8.13 None 158
02.08.11 Govindaraj 975590D 70 No No 4 NA NA 15.07.11 1000 NA NA NA no 159
16.4.13 Kasinathan M 558476C 65 Uro1 yes No 1.4.13 1500 17.4.13 None 165
08.08.11 Rajakili 917075D 80 No No Asthma 24 yes 1000 10.08.11 NA 1 157
20.07.11 Akinchan Ghosh 979145D 67 No No 24 17.06.11 1000 21.07.11 no 163
03.01.12 Yogendra Prasad 075050F 43 No No 24 22 01-Jun 1500 4.01.12 NA NA NA Not done 161
11.02.13 John Ravindran J 566269D 53 Uro1 No Yes CUR 12.02.13 0.5 600 181
26.09.11 Ashutosh Bihari Sahay 017726F 58 Uro1 No 2011 8 30.6.11 2000 27.09.11 NA NA NA Not done 167
17.08.11 Chinna Durai K Dr 888314D 67 17 years 12 years IHD 36 CUR 02.09.11 4 7 300 157
23.02.12 Rajagopal G 106707F 50 No No fracture tibia 10.01.12 1000 failed 3 165
15.10.12 Karmbeer Parsad Gupta249989F 63 Uro1 Yes Yes Dyslipidemia 14.09.12 2000 17.10.12 160
19.12.11 Kanailal Paik 085758F 70 Uro1 No No 24 1 2009 1000 20.12.11 164
16.9.13 Muniswamy R 057598B 75 Uro1 Yes Yes 1 3 No No 29.7.13 1400 17.9.13 None 169
28.07.12 Niranjan Mondal 239277F 73 Yes No 12 19.6.12 1200 176
20.11.12 Ramaswamy P 299491F 75 No No 18.09.13 1000 22.11.12 Not done 158
17.08.11 Ramji Sahay 979735D 73 Uro1 No No Pulmonary 24 18 18 23.06.11 1000 19.08.11 168
26.09.12 Lakshmikanthan K S 746454B 79 No No IHD post CABG Apr-12 1000 156
05.08.12 Ramesh Jha 256223F 58 yes no 24 14.07.12 1000 06.08.12 Failed 1 170
2.8.13 Ponnusamy C 575780D 74 Yes No Nil 48 21 Yes Yes 8.7.13 1200 2.8.13 Failed 1 155
13.09.11 Zaffarullah Khan 975415D 49 Yes No Dyslipidemia 12.07.11 1000 09.09.11 164
23.10.12 Mongal Banerjee 288159F 70 CUR 24.10.12 7.5 162 439 165
13.03.13 Dibakar Pradhan 426184F 57 No No Smoker 9.2.13 1000 14.3.13 165
12.9.13 Mohammed Naimuddin 642026F 70 Uro1 No No 36 25 No No 28.8.13 1000 13.9.13 None 160
10.09.12 Abdul Satter 251312F 65 Uro1 yes no Smoker 9 19.6.12 1000 14.09.12 failed 1 172
27.08.12 Prabhu Sharan Singh 059612F 60 No Yes Smoker 12 Yes Yes 14.06.12 1000 28.08.12 NA NA NA Not done 171
16.7.13 Thamarai A 460948D 69 Uro1 No Yes 36 28.5.13 1000 18.7.13 150
4.8.13 Bijoy Mochary 624013F 44 Yes Yes 180 34 23.12.12 1000 None 168
26.03.12 Govindharaj 099009F 72 No Yes Hep B and  48 11-Nov 1000 failed1 157
27.8.13 Perumal V 639522F 55 No No 1 17 No No 7.8.13 1000 1 Failed 169
05.06.12 Radhakrishnan 147448F 78 No No Hernia 3 Yes 2.04.12 1000 6.06.12 Failed 1 171
06.06.12 Ismail S 101213F 66 Yes Yes NA 15.12.12 1000 failed 3 164
10.12 Asim Kumar Ukil 317152F 63 Uro1 No No asthma 6 11.10.12 1000 9.11.12 418 175
05.11.12 Harka Maan Tamang 313408F 60 Uro1 Yes No Nil 13.09.12 1500 16.11.12 Failed 2 160
10.09.12 George 667305old 55 Uro1 no no asthma 3 16.06.12 1000 failed 2 170
28.7.13 Ashok Kumar 017672C 52 No Yes Nil 14 No No 24.4.13 1000 29.7.13 7.2 93 708 1 178
11.01.12 Samirendra Nath Chakr 081150F 71 No yes 36 12 3 Not catheteCUR 16.2.12 0.5 454 NA 170
25.07.11 Dhanivel 962656D 58 No 2 year 2 22.05.11 1000 28.07.11 1 168
20.12.11 Naser Ali Mondal 086806F 72 No No 6 26 3 Oct-11 1200 21.12.11 failed 2 157
28.11.12 Abraham Savari Muthu 384113D 76 No Yes IHD 18 8.11.12 1800 29.11.12 152
20.12.11 Narayan Nishad 093050F 65 No 2 24 30.10.11 1000 22.12.11 NA NA NA 156
17.09.12 Ganesan A 726830C 70 Yes Yes Left BKA 24 15.06.12 1500 12.10.12 Failed 2 160
12.11.12 Ilaiah 291607F 81 Uro1 No No 12 No No 1000 14.11.12 Not done 161
16.7.13 Yousuf Hussain D 616108F 66 Yes Yes Obesity 1 10 Yes Yes 18.6.13 1000 17.7.13 once failed 153
14.03.12 Naba Kumar Mandal 143565F 70 No Yes 36 12-Jan 1500 17.03.12 167
11.01.12 Paulswamy 387221B 72 Yes No 6 No No 26.02.11 1000 12.01.12 Not done 164
5.11.12 Hari Krishnan P 088758D 70 Uro1 No Yes 48 yes no 8.12 1000 6.11.12 and 15.1.13 Failed 1 167
6.8.13 Gopal S 619314F 65 Uro1 No No Nil 6 16 No No 6.13 1000 Failed 2 158
29.04.12 Ganesan C 818609B 82 No No Pulmonary TB, Atrial fibrillation, IHD 25.02.12 1000 161
17.09.12 Ganesh 049206D 67 Uro1 Yes Yes 60 Jul-12 1000 17.09.12 172
21.11.12 Gauranga Parva 334153F 65 No Yes 6.11.12 1000 22.11.12 160
22.10.12 Khader Basha H 240676F 67 Uro1 No Yes Hypothyroid 1000 23.10.12 160
05.06.12 Chinnadurai M 190284F 74 No No CRF due to  12 Apr-11 1000 167
26.09.12 Narasimha Reddy 798904C 70 Uro1 Yes No Smoker 60 Yes Yes 12-Apr 1000 28.09.12 failed 1 161
30.08.12 Karunakaran V 754285D 84 Uro1 No No 36 20.08.12 1000 31.08.12 168
29.04.12 Chinna Kulandai 148311F 64 No Yes 36 12-Mar 1000 30.05.12 6 160 489 160
03.08.11 Devarajulu T 776309C 70 6 years 6 years 12 04.07.11 1000 04.08.11 1 168
08.10.12 Vaddu 236137F 60 No No 2 May-12 1000 10.10.12 Not done 161
24.09.12 Rajamani K 240747F 67 Uro1 No No Smoker 12 Jul-12 1000 25.09.12 160
weight(Kg) BMI BP(Hgmm) DRE USG prosta  TRUS Wd(mmTRUS Ht(mm) TRUS L(mm) Pros vol(cc) IPP Gland resectedcreatinine PSA urine C/S operation
72 25.8 110/80 20 22 28.4 19.1 30.7 8.71 na 5 1.28 0.428 Mixture of organism TURP
43 17.9 150/80 15 35.2 18.9 36.1 12.5 0 5 2.6 E coli, Pseudomonas aeruginosa, NTURP
60 22.9 130/90 15 NA 35.9 23.2 29.8 13 0 NA 1.09 E.coli TURP
62 24.8 130/90 20 33.2 19.8 38 13 3.71 0 0.78 NA 35000 GNB TUIP
65 23.9 120/80 20 30.5 21.4 39.6 13.5 0 3 1.83 NA >100000 E coli ESBL+ TURP
61 20.9 150/80 25 19.7 38.5 36.5 14.5 0 NA 3.01 E coli, enterobacter1, enterobacte  TUIP
46 17.5 130/90 25 NA 38.1 22.8 33.5 15.2 0 8 1.13 No growth TURP
65 23.9 140/70 15 37.3 28.3 27.9 15.4 0 0 2.74 NA >100000 E coli ESBL+ & Enterococ TUIP
43 17.7 140/90 25 10.1 37.3 23.2 34.9 15.8 0 3.28 1.53 NA >100000 E coli ESBL TURP
50 19.1 140/90 20 39.6 21 37.5 16.3 0 6 0.99 NA No growth TURP
78 27.6 130/80 15 NA 36.9 23.3 39.1 17.6 0 6 1.09 No growth TURP
75 26 190/90 25 NA 37.6 22.4 42.1 18.5 0 4 1.07 NA Contaminants TURP
61 24.4 140/90 20 NA 44.1 22.9 35.5 18.7 0 3 1 Mixture of organism TURP
48 18.3 110/80 25 NA 42.4 24.1 37.9 20.3 6.98 6 1.27 5.15 >100000 Pseudomonas and E coli TURP
48 18.5 138/80 20 36.2 24 45.3 20.6 7.1 6 1.05 Enterococcus and Aeromonas TURP
71 26.1 120/70 20 NA 26.3 42.8 35.8 21 0 2 1.2 Contaminants TURP
67 25.5 136/90 20 NA 42.2 22.6 42.5 21.2 5 10 1.88 Contaminants TURP
37 14.3 110/60 20 44.4 24.5 37.6 21.3 0 3.7 2.93 NA >100000 E coli ESBL TURP
70 25.1 110/70 20 45.5 30.7 30.1 22 0 4 14 NA Colonization 4 organism TURP
54 19.8 130/90 25 41.5 24 42.6 22.2 10.3 10 1.25 NA No growth TURP
47 19.6 130/80 20 41.3 20.3 51 22.3 9 15 5.3 Enterococcus and E coli TURP
54 24 130/90 50 45.1 25.3 38.2 22.9 6.84 13.5 1.59 NA >100000 Proteus mirabilis TURP
82 30.9 140/70 20 NA 41 26.3 41.3 23.3 0 8 1.2 Morganella morganii 35000cfu/m TURP
60 22.9 140/90 20 29 41.2 22.7 47.9 23.4 6.1 5 5.7 Pseudomonas and enterococcus TURP
59 23.3 140/90 25 47 23 42.4 24 3.2 NA 1.8 Contaminants TURP
38 14.1 130/80 20 93 36.5 28.7 46.1 25.2 13 16 1 Pseudomonas aeruginosa, Entero        TURP
60 22 140/80 20 39.79 42.5 27.9 41.6 25.9 na 9 1.18 Klebsiella >100000 TURP
55 20.2 120/90 25 42.5 32.4 36.2 26.1 0 6.5 1.04 10.2 >100000 Klebsiella TURP
44 16.4 140/90 20 NA 44.8 28 40.8 26.8 na 2 0.84 Pseudomonas >100000cfu panres TURP
54 21.6 120/70 25 47.6 26 41.9 27.1 0 6 1.2 Contaminants TURP
99 35.1 140/80 20 NA 41.3 28.4 44.8 27.5 0 8 1.3 Candida Tropicalis TURP
54 22.5 130/70 25 55 40.5 30.4 43.4 28 6 26 0.88 13.4 E coli >100000 ESBL TURP
70 27.7 120/80 35 66 43.3 30.7 42.5 29.5 0 5 1.2 Psuedomonas amd NFGNB TURP
59 20.2 124/72 20 Bladder cal 45.5 30.1 41.8 29.9 0 NA 1.77 NA 45000 Enterococcus TURP
60 23.7 140/80 30 40 43 27.2 49.3 30.2 9.21 10 1.73 NA >100000 Enterococcus and KlebsieTURP
68 22.5 128/80 20 24.3 44 24.5 57.2 32.3 4.1 5 3.23 Mixture- Enterococcus, Klebsiella,   TURP
45 17.8 120/76 15 NA 44.9 30.1 47.1 33.3 11 14 1.1 4.93 Contaminants TURP
46 16.3 110/70 40 80 47 32.6 44.2 35.4 2.1 16 3.4 Enterococcus, E Coli (ESBL) TURP
54 22.5 130/80 20 NA 48.5 31 45.4 35.8 Intravesica   20 1.24 Enterobacter, Enterococcus, NFGNTURP
58 20.3 160/90 30 NA 46.4 31.2 47.4 35.8 3.94 10 1.37 Contaminants TURP
42 15.4 110/80 30 47.9 30 48.1 36.1 11.1 10 1.27 22.1 >100000 Enterococcus and EnteroTURP
60 24.7 140/90 30 NA 47.2 30.3 48.9 36.5 7 18 1.1 Serretia, E coli TURP
60 22 110/90 30 NA 46.2 29.4 52.1 37 10.9 20 1.08 Pseudomonas >100000cfu TURP
67 24.6 140/90 90 42.9 31 53.6 37.3 13.3 24 0.89 4 No growth TURP
55 20.2 160/90 20 50.8 32 44.3 37.7 5 16 0.97 Contaminants TURP
60 24 150/90 25 47.6 32.3 47.4 38.3 7.06 26 1.32 NA >100000 E coli ESBL+ TURP
68 23 130/80 40 48 42.3 32.6 54.1 38.9 11 15 1.29 Contaminants TURP
55 22.9 160/90 30 NA 47.6 31.8 49.3 39 5.1 12 1.1 No growth TURP
45 20 130/80 30 50.5 29.3 51 39.6 3.1 25 1.8 Enterobacter, Klebsiella TURP
63 21.8 110/80 25 39.8 33.5 57.4 40 18.3 22 1.09 10.9 >100000 Enterococcus and E coli TURP
60 22 126/86 40 NA 43.8 36.9 47.6 40.2 9 13 0.94 Contaminants TURP
62 23.1 140/80 30 NA 50.4 31 49.5 40.5 2.2 22 1.12 E coli and NFGNB >100000 TURP
50 19.5 120/70 40 44.1 33.5 52.8 40.8 16 26 1.16 7.02 Contaminants TURP
56 21.9 130/80 30 43.5 32 56.2 40.8 10 29 1.3 klebsiela TURP
68 24.4 140/90 30 47 51 26.2 52.9 41.1 4.8 25 0.95 1.07 Contaminants TURP
92 33.8 150/30 50 80 43.9 33.2 55.7 42.5 10 23 0.94 Contaminants TURP
54 21.6 150/90 30 80 54.2 36 42.2 43 5.32 17 1.4 NA >100000 Ecoli 1&2 ESBL TURP
45 17.1 120/80 30 37 51.3 43.4 43.1 5 24 0.94 NA 600 Enterococcus TURP
66 25.1 140/90 30 63 42.8 32.9 58.6 43.2 18.1 30 1 Contaminants TURP
68 23.5 130/90 30 45 49.1 36.4 46.3 43.3 8.15 27 1.02 Klebsiella >100000 sensitive only t  TURP
47 18.8 110/60 40 47.9 34.2 51.2 43.9 12.7 20 1.27 5.45 >100000 E coli , NFGNB TURP
46 18.2 130/80 40 58 54.7 31.5 49.8 44.9 1 30 0.9 NFGNB1, NFGNB2 TURP
63 23.1 130/80 40 NA 47.3 32.8 55.6 45.1 17.1 17 0.81 NA Contaminants TURP
39 15.8 120/80 40 107 48.4 37.6 47.6 45.3 10 17 1.2 Pseudomonas TURP
55 20.7 120/80 25 NA 49.9 38 46.4 45.9 30 0.6 E coli, proteus vulgaris TURP
45 17.4 130/80 30 36 49.4 32.9 54.5 46.3 6 20 1.4 E.coli and Kleb TURP
73 22.3 100/70 30 42 52.4 34.2 49.4 46.4 0 21 1.39 No growth TURP
69 24.7 150/90 50 NA 52.1 34 50.7 46.9 4.1 20 3.1 Pseudomonas aeruginosa 1700 TURP
64 26 130/80 35 53.7 36.4 45.8 46.9 2 12 1.1 Contaminants TURP
58 21.3 130/80 40 89 45.5 33.3 59.4 47 10.1 15 1.04 enterobacter >100000, sen to coli   TURP
60 23.4 170/80 30 55.6 33.4 48.5 47.2 0 8 1.59 Klebseilla >100000 and Enterococ TURP
54 20.1 130/90 40 NA 49.8 33.6 54 47.3 4.9 28 1.3 Pseudomonas aeruginosa 9000cfu      TURP
69 24.2 130/80 25 50 38.6 47.4 47.8 2.93 15 1.13 NA TURP
64 20.7 130/70 25 NA 46.5 37.9 53.5 49.4 12 20 1.54 Pseudomonas aeroginosa 4500 TURP
36 14.4 110/70 45 34 46.8 34.7 59.9 50.9 6.46 19 1.01 6.05 >100000 Enterobacter TURP
60 21.3 110/70 45 72 55.9 35.4 49.3 51 3.9 24 1.4 E coli >100000 amika, ertapenem, TURP
55 22.6 130/90 35 57.6 33.9 50 51 10.5 18 1.2 >100000 Morganella morganii, En  TURP
63 21.8 130/80 25 NA 54.1 40.2 46 52.3 5.1 22 0.9 No growth TURP
56 23.3 100/60 35 Enlarged 48.7 37.6 55.1 52.7 13.5 20 1.67 NA >100000 Enterococcus and E coli TURP
54 20.1 140/80 25 NA 57.1 39.4 45 52.9 2.1 6 1.3 E.coli and pseudomonas TURP
75 27.5 160/90 25 88 46.7 36.6 59.5 53.2 na 36 1.17 2.73 >100000 Enterococcus. TURP
58 21.3 120/70 40 46.6 33.2 66.3 53.6 20.4 35 1.1 NA Contaminants TURP
48 18.8 140/90 40 49 35.5 59.4 54 12.6 20 1.02 NA >100000 Klebsiella TURP
85 28.7 120/70 30 NA 53.7 41.1 47.4 54.7 15 40 1.2 >100000 Enterococcus, Klebsiella,  TURP
67 22.9 136/90 40 NA 50 33.2 64.7 56.1 20.2 39 1.51 Pseudomonas aeruginosa TURP
52 23.1 150/90 40 50 49 39.8 56.3 57.5 16.7 26 1.48 NA 9400 Enterococcus and Morganel  TURP
60 21.3 130/90 30 48.4 37.9 60.1 57.7 18.6 31 1.07 12.1 No growth TURP
62 25.2 142/90 40 52.1 39.6 55.8 60.2 19.5 1.16 Klebsiella >100000 TURP
74 25.9 120/80 70 55.3 35.5 58.8 60.3 4.07 12 1.44 7.88 E coli ESBL+ >100000 amikacin, ce   TURP
70 23.9 140/80 30 63 50.3 40.2 57.2 60.4 4 26 1.05 6.72 No growth TURP
56 20.8 140/90 30 76 54.2 37.8 58.1 62.2 16 52 1.11 Klebsiella, E coli, Enterocoiccus TURP
61 19.9 130/80 40 NA 57.6 36.3 57.5 62.8 na 25 0.94 NA No growth TURP
51 19.9 110/70 40 NA 52.1 42.7 54.6 63.5 7.87 17 1.32 NA >100000 Enterococci and Klebsiel   TURP
59 20.4 130/90 40 NA 52.2 42.9 54.4 63.7 9.3 29 1.18 Citrobacter TURP
75 23.7 120/80 30 44.8 42.4 64.1 63.7 20.6 26 1.19 NA >100000 NFGNB TURP
61 21.1 130/80 40 NA 47.6 43.2 60.2 64.8 11 29 1.1 Contaminants TURP
71 25.2 130/80 30 38 54.5 42.1 55 66 6.01 20 1 Mixture of organism TURP
60 24.3 120/80 25 NA 54.7 41.8 55.6 66.4 11.5 30 1.1 10.9 No growth TURP
53 22.9 140/90 35 60 58.2 42.1 52.8 67.6 26 1.31 11.18 Yeast- candida tropicalis TURP
50 20.5 140/90 40 NA 53.7 44.5 54.4 68 5 52 1.4 20.6 E. coli sensitiveto amikacin and NFTURP
75 29.3 200/110 30 62 49.5 42.1 64.9 70.7 12 37.5 1.9 12.5 Pseudomonas >100000 Resistant  TURP
42 16.2 120/70 50 42 52.4 41.3 62.7 70.9 na 26 0.95 7.61 8200 Entrococcus and NFGNB TURP
90 38.4 130/60 35 53.9 44.5 57.9 72.7 16.9 47 1 4.23 >100000 E coli 1&2 and Pseudomo  TURP
66 23.7 130/80 50 59.9 38.1 61.1 72.9 14 41 1.32 Klebsiella >100000 TURP
62 23.1 110/70 40 108 52.1 45.1 60 73.7 19 32 1.2 E coli 24000CFU/ml ESBL amika TURP
50 17.9 160/90 35 50 43.7 65.3 74.6 na 25 and 7 0.85 7.89 Contaminants TURP
48 19.2 100/70 25 64 49 47.4 64.3 78.2 18.9 27 1.02 22.8 >100000 Enterococcus NFGNB sen  TURP
60 23.1 130/80 40 55.3 47.1 59.8 81.6 3 16 1.2 Klebsiella >100000 TURP
67 22.6 140/90 45 55 44.1 64.6 81.8 10.3 39 1.28 1.08 E coli, Enterococcus, Klebsiella TURP
47 18.4 140/90 50 58 41.3 66.4 83.3 4.7 50 1.54 NA No growth TURP
52 20.3 140/90 45 105 61 44.3 60.7 85.6 5 31 1.31 4.7 >100000 E coli Cipro Resistant TURP
63 22.6 110/80 20 52 48.3 74.3 97.5 7 52 2.72 Proteus and Enterococcus TURP
47 18.1 130/80 50 70 57.3 47.5 71.1 101 18 75 1 E coli, Klebsiella >100000 ESBL+ TURP
68 24.1 126/84 40 75.7 45.7 62.3 113 10.1 60 1.2 E coli >100000 ESBL TURP
65 25.4 140/90 40 65.9 41.3 80.1 114 10 68 1.67 Pseudomonas and enterococcus TURP
55 19.5 110/80 35 61 52.6 54.9 76.4 115 10.2 51 1.5 E coli60000 Amik Genta NFT TURP
51 19.7 110/70 30 145 70.2 51 72.5 136 22.9 104 1.24 39.9 Providencia 8500 TURP
49 19.1 130/70 60 136 75.1 55.4 79.1 172 19 36 2.78 143 No growth TURP
biopsy Post op creat  Post op culture Bood groupGlycine useSaline Post op Na PVR post o STATUS
Hyperplasia with chronic prostatitis 1.01 O+ 50 Not used Catheter free
Nodular hyperplasia 2.7 Pseudomonas B+ 40 6 828 CISC
Benign nodular hyperplasia 1.32 Catheter free
NA 0.76 No growth NA 10 Not used Catheter free
Hyperplasia 1.62 No growth B- 16 Not used 39 Catheter free
NA 2.37 E coli 300 cfu/ml O+ NA NA 136 41 Catheter free
Hyperplasia NA Contaminants B+ 34 Not used Had AUR af      Catheter free
NA 2.84 >100000 E coli ESNA 14 Not used Catheter free
Hyperplasia 1.29 No growth NA 20 Not used 74 Catheter free
Hyperplasia with prostatitis NA No growth A+ 28 Not used NA 900 CISC
Hyperplasia NA No growth B+ 26 Not used Catheter free
Hyperplasia 1.1 Contaminants B+ 38 Not used 116 102 Catheter free
Hyperplasia NA E Coli AB+ 24 Not used Catheter free
Hyperplasia NA Contaminants NA 12 Not used Catheter free
Hyperplasia and prostatitis NA Contaminants A+ 20 Not used NA Catheter free
Hyperplasia 1.3 Klebsiela B+ 104 Catheter free
Hyperplasia NA Contaminants A+ NA Not used 110 Catheter free
Hyperplasia NA NA 26 Not used 133 Catheter free
Hyperplasia NA 45000 Enterococ B+ 14 Not used Catheter free
Hyperplasia NA No growth B+ 40 Not used NA 24 Catheter free
Hyperplasia and prostatitis 5.19 No growth O+ 30 Not used 135 Indwelling catheter
Hyperplasia with mild chronic prostatit 1.2 Contaminants NA 36 Not used NA 28 Catheter free
Hyperplasia focal prostatitis 1.25 Enterococcus, co  B+ 36 Not used 133 Catheter free
Hyperplasia and prostatitis 1.6 No growth O+ Not used 6 26 Catheter free
Hyperplasia and prostatitis 1.7 No growth O+ NA Not used 28 Catheter free
Hyperplasia NA No growth O+ 34 Not used Catheter free
Hyperplasia with suburothelial chronic inflammation B+ 30 Not used Catheter free
Hyperplasia with chronic prostatitis NA 12000 Enterococ NA 10 Not used 43 Catheter free
Hyperplasia NA O+ 220ml CBD CIC
Hyperplasia NA Contaminants A+ 20 Not used NA Catheter free
Hyperplasia NA Enteroococcus O neg 40 Not used Catheter free
Hyperplasia NA E coli >100000 esA+ 50 Not used Catheter free
Benign nodular hyperplasia NA No growth B+ 20 Not used Catheter free
Hyperplasia NA NA NA Indwelling catheter
Hyperplasia 1.62 Contaminants B+ 23 Not used NA NA Catheter free
Hyperplasia and prostatitis 3.03 Enterococci and  A+ 26 Not used 136 192 Catheter free
Hyperplasia No growth AB+ 38 Not used Catheter free
Hyperplasia 1.99 Enterococcus >10B+ 34 Not used 133 800 CBD
Hyperplasia NA No growth O+ NA NA 68.6 Catheter free
Hyperplasia Contaminants NA 19 Not used 70 Catheter free
Hyperplasia NA Contaminants B+ 16 Not used Catheter free
Hyperplasia NA Enterococcus, E cA+ 30 Not used Catheter free
Hyperplasia with focal squamous metaplasia AB+ 137 Catheter free
Hyperplasia Contaminants 40 Not used Catheter free
Hyperplasia and prostatitis NA NA O+ 26 Not used Failed TWOCatheter free
Hyperplasia with mild chronic prostatit NA Contaminants A+ 42 Not used 126 30 Catheter free
Hyperplasia and prostatitis 1.06 E coli  >100000, E  O+ 40 Not used 87 Catheter free
Hyperplasia Contaminants A neg NA Catheter free
Hyperplasia 1.8 Contaminants A+ CBD- Did not void 
Hyperplasia with mild chronic prostatit NA 31500 E coli ESBLNA 28 Not used NA NA Catheter free
Hyperplasia NA No growth O+ 30 Not used 21 Catheter free
Hyperplasia Contaminants B+ 36 Not used 38 Catheter free
Hyperplasia with mild chronic prostatiti NA Contaminants AB+ 46 Not used 133 14 Catheter free
Hyperplasia non specific prostatitis 1.8 enterococcus A+ 52 Not used 129 98 Catheter free
Hyperplasia NA No growth NA 36 Not used NA Catheter free
Benign nodular hyperplasia NA Contaminants B+ NA Catheter free
Hyperplasia 1.35 No growth B+ 20 Not used 136 141 Catheter free
Hyperplasia NA Contaminants O+ 32 Not used 133 Catheter free
Hyperplasia 1 No growth A+ 68 Not used NA Catheter free
Hyperplasia NA O+ 66 Not used 125 18 Catheter free
Hyperplasia with moderate granulomat    NA O+ 34 Not used 121 Catheter free
Benign nodular hyperplasia NA Contaminants A+ 34 Catheter free
Hyperplasia with prostatitis 0.85 No growth AB+ 20 Not used 68 Catheter free
Hyperplasia and prostatitis 1 Contaminants A+ 44 Not used Catheter free
Hyperplasia Contaminants B+ Catheter free
Hyperplasia 1.4 Contaminants O+ 40 10 51 Catheter free
Hyperplasia 1.22 Enterococcus O+ 20 Not used 73 Catheter free
Hyperplasia 2.8 Contaminants B neg Not used 52 36 Catheter free
Hyperplasia 1 Pseudomonas 15  A+ 38 Not used 37 Catheter free
Hyperplasia and prostatitis NA Contaminants NA 30 Not used Catheter free
B+ 24 Not used 67 Catheter free
Hyperplasia with focal prostatitis NA Contaminants A+ Catheter free
A+ 74 Not used 126 Catheter free
Hyperplasia 1.55 Contaminants O+ 32 Not used 134 Catheter free
Hyperplasia with prostatitis NA No growth O+ 44 Not used 40 Catheter free
Hyperplasia NA NA O+ Catheter free
Hyperplasia with prostatitis 0.97 B+ 34 Not used 128 Catheter free
Chronic prostatitis with granuloma Contaminants B+ NA NA Catheter free
Hyperplasia with focal prostatitis NA No growth A+ NA NA 139 44 Catheter free
Hyperplasia and prostatitis 0.9 No growth B+ 24 Not used Catheter free
Hyperplasia NA No growth A+ 56 Not used NA NA Catheter free
Hyperplasia with prostatitis NA Contaminants NA 88 Not used NA Catheter free
Hyperplasia NA No growth NA 46 Not used NA Catheter free
Hyperplasia NA Coagulase neg st O+ 50 Not used 130 Catheter free
Hyperplasis NA E coli >100000 esO+ NA NA 138 Catheter free
Hyperplasia NA 21000 Enterococ  O+ Catheter free
Hyperplasia NA No growth A+ 36 Not used NA Catheter free
Benign nodular hyperplasia NA Contaminants B+ NA NA Catheter free
Hyperplasia E coli 2500 ESBL+A+ Catheter free
Benign nodular hyperplasia NA Enterococcus A+ 42 Not used Catheter free
Hyperplasia NA E coli >100000 esB+ 36 Voided goo  Catheter free
Hyperplasia with granulomatous prosta 0.96 Contaminants B+ 44 Not used NA 33 Catheter free
Hyperplasia 1.29 No growth A+ 44 Not used Catheter free
Hyperplasia NA Contaminants 44 Not used NA 69 Catheter free
Hyperplasia with prostatitis 1.46 Contaminants B+ 34 Not used 77 Catheter free
Hyperplasia 1.28 No growth B+ yes Not used 12 Catheter fr Had submeatal stenosis
Hyperplasia Chronic prostatitis B+ 49 Catheter free
Hyperplasia NA Contaminants A+ 56 Not used Catheter free
Hyperplasia with prostatitis NA Contaminants A+ 28 Not used Catheter free
Hyperplasia with prostatitis 1.5 No growth B+ 56 Not used Catheter free
Hyperplasia with prostatitis 1.87 A+ 50 Not used Catheter free
Hyperplasia 0.98 NA O+ 46 Not used 124 80 Catheter free
Hyperplasia with mild chronic prostatiti NA No growth A- 48 Not used NA 40 Catheter free
Hyperplasia NA Contaminants O+ 56 Not used 141 87 Catheter free
Hyperplasia with prostatitis 1.3 Enterococcus 850AB+ Not used Yes 125-133 Catheter free
Hyperplasia with prostatitis 0.92 No growth A+ 30 Not used 136 Catheter free
Hyperplasia with mild chronic prostatit NA No growth NA 40 Not used 139 Catheter free
Hyperplasia and prostatitis 0.93 Contaminants O+ 28 34 132 Catheter free
Hyperplasia NA Contaminants O+ 46 Not used NA Catheter free
Hyperplasia 1.56 >100000 E coli ESB+ 48 Not used 137 Catheter free
Hyperplasia with chronic prostatitis NA No growth O+ 62 Not used NA 27 Catheter free
Hyperplasia and prostatitis 2.61 Proteus Mirabilis O+ 56 Not used 136 Catheter free
Hyperplasia with focal squamous metap 1.09 O+ 54 Not used 121 77 Catheter free
Hyperplasia NA pseudomonas, e  AB+ 70 Not used 133 Catheter free
Hyperplasia and prostatitis 2.25 Enterococcus >100000 6 72 128 Catheter free
Hyperplasia Enterococcus750NA 30 34 Catheter free
Hyperplasia with acute on chronic pros NA O+ 66 Not used 132 Catheter free
Hyperplasia 2.07 Pseudomonas a 1O+ 64 Not used 126 24 Catheter free
